{"id":54782,"date":"2023-03-13T21:03:16","date_gmt":"2023-03-13T20:03:16","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/"},"modified":"2023-03-13T21:03:16","modified_gmt":"2023-03-13T20:03:16","slug":"angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/","title":{"rendered":"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023"},"content":{"rendered":"
\n

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open on Thursday, March 30, 2023. The Company\u2019s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.\n<\/p>\n

<\/a><\/p>\n

\nTo participate in the conference call, dial 1-877-407-0784 (domestic) or +1- 201-689-8560 (international) and refer to the passcode 13737051.\n<\/p>\n

\nThis conference call will also be webcast and can be accessed from the \u201cInvestors\u201d section of the AngioDynamics website at www.angiodynamics.com<\/a>. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.\n<\/p>\n

\nA recording of the call will also be available from 11:00 a.m. ET on Thursday, March 30, 2023, until 11:59 p.m. ET on Thursday, April 6, 2023. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13737051.\n<\/p>\n

\nAbout AngioDynamics, Inc.<\/b>\n<\/p>\n

\nAngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients.\n<\/p>\n

\nThe Company\u2019s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor:<\/p>\n

AngioDynamics, Inc.
\n
Stephen Trowbridge, Executive Vice President & CFO
\n
(518) 795-1408\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54782","6":"format-standard","7":"category-industry"},"yoast_head":"\nAngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-13T20:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230313005747\/en\/664620\/21\/ANGO_-_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023\",\"datePublished\":\"2023-03-13T20:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/\"},\"wordCount\":274,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005747\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/\",\"name\":\"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005747\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\",\"datePublished\":\"2023-03-13T20:03:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005747\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230313005747\\\/en\\\/664620\\\/21\\\/ANGO_-_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/","og_locale":"en_US","og_type":"article","og_title":"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023 - Pharma Trend","og_description":"LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body\u2019s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the third quarter of fiscal year 2023 before the market open ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-13T20:03:16+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230313005747\/en\/664620\/21\/ANGO_-_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023","datePublished":"2023-03-13T20:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/"},"wordCount":274,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230313005747\/en\/664620\/21\/ANGO_-_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/","url":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/","name":"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230313005747\/en\/664620\/21\/ANGO_-_Logo.jpg","datePublished":"2023-03-13T20:03:16+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230313005747\/en\/664620\/21\/ANGO_-_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230313005747\/en\/664620\/21\/ANGO_-_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/angiodynamics-to-report-fiscal-2023-third-quarter-financial-results-on-march-30-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AngioDynamics to Report Fiscal 2023 Third Quarter Financial Results on March 30, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54782","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54782"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54782\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54782"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54782"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54782"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}